COVID-19 Infections Clinical Trial
Official title:
Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial
In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure.
COVID-19 is a novel coronavirus that was initially outbreak in Wuhan, China. Severe acute
respiratory infection with COVID-19 causes severe acute respiratory failure with substantial
mortality. Currently, the standard care is supportive care, and no treatment is proven to be
effective for this condition.
Glucocorticoid therapy is widely used among critically ill patients with other coronavirus
infection such as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory
syndrome). However, whether glucocorticoid improved the outcome of COVID-19 remains unknown.
We hypothesized that glucocorticoid would improve the prognosis of patietns with COVID-19.
In this study, critically ill patients with COVID-19 were enrolled and randomized to receive
ether standard care or standard care in combination with methylprednisolone therapy. The
primary outcome is the difference of Murray lung injury score between two groups.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04584437 -
Treatment of Covid-19 Infections Using Vitality Therapy or the Bible Cure
|
N/A | |
| Completed |
NCT04810117 -
Monitoring the IgG/IgM Antibodies in COVID-19 Patients
|